Display options
Cite
Walsh CE, Nienhuis AW, Samulski RJ, et al. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest. 1994;94(4):1440-8doi: 10.1172/JCI117481.
Walsh, C. E., Nienhuis, A. W., Samulski, R. J., Brown, M. G., Miller, J. L., Young, N. S., & Liu, J. M. (1994). Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. The Journal of clinical investigation, 94(4), 1440-8. https://doi.org/10.1172/JCI117481
Walsh, C E, et al. "Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector." The Journal of clinical investigation vol. 94,4 (1994): 1440-8. doi: https://doi.org/10.1172/JCI117481
Walsh CE, Nienhuis AW, Samulski RJ, Brown MG, Miller JL, Young NS, Liu JM. Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest. 1994 Oct;94(4):1440-8. doi: 10.1172/JCI117481. PMID: 7929819; PMCID: PMC295276.
Copy Download .nbib Format: NLM
Share it on
Full text links
American Society for Clinical Investigation Free PMC Article

J Clin Invest. 1994 Oct;94(4):1440-8. doi: 10.1172/JCI117481.

Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector.

The Journal of clinical investigation

C E Walsh, A W Nienhuis, R J Samulski, M G Brown, J L Miller, N S Young, J M Liu

Affiliations

  1. Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.

PMID: 7929819 PMCID: PMC295276 DOI: 10.1172/JCI117481
Free PMC Article

Abstract

Fanconi anemia (FA) is a recessive inherited disease characterized by defective DNA repair. FA cells are hypersensitive to DNA cross-linking agents that cause chromosomal instability and cell death. FA is manifested clinically by progressive pancytopenia, variable physical anomalies, and predisposition to malignancy. Four complementation groups have been identified, termed A, B, C, and D. The gene for the FA complementation group C, FACC, has been cloned. Expression of the FACC cDNA corrects the phenotypic defect of FA(C) cells, resulting in normalized cell growth in the presence of DNA cross-linking agents such as mitomycin C (MMC). Gene transfer of the FACC gene should provide a survival advantage to transduced hematopoietic cells, suggesting that FA might be an ideal candidate for gene therapy. We demonstrated efficient transduction, expression, and phenotypic correction in lymphoblastoid cell lines derived from FA (C) patients using a recombinant adeno-associated virus (rAAV) vector containing the FACC gene. Molecular characterization of the transduced FACC gene showed an intact unrearranged proviral genome with expression sufficient to normalize cell growth, cell cycle kinetics and chromosomal breakage in the presence of MMC. These observations were extended by testing rAAV transduction in hematopoietic progenitor cells. Peripheral blood CD34+ cells isolated from a FA (C) patient and transduced with rAAV/FACC virus yielded 5-10-fold more progenitor colonies than mock-infected cells, consistent with genetic "rescue" of corrected cells. This is the first demonstration of rAAV gene correction in primary human hematopoietic progenitor cells and has important implications for gene therapy of hematopoietic disorders, specifically FA.

Cited by

References

  1. EMBO J. 1991 Dec;10(12):3941-50 - PubMed
  2. Nature. 1992 Apr 30;356(6372):763-7 - PubMed
  3. Humangenetik. 1964;1(2):194-6 - PubMed
  4. Cancer Res. 1973 Aug;33(8):1829-36 - PubMed
  5. Br J Haematol. 1978 Oct;40(2):277-87 - PubMed
  6. Mutat Res. 1981 Feb;80(2):373-80 - PubMed
  7. Cytometry. 1982 Mar;2(5):291-7 - PubMed
  8. Proc Natl Acad Sci U S A. 1982 May;79(9):2942-6 - PubMed
  9. Cancer Res. 1982 Oct;42(10):4000-6 - PubMed
  10. Hum Genet. 1982;62(4):327-32 - PubMed
  11. Am J Hum Genet. 1985 Sep;37(5):1022-30 - PubMed
  12. Nucleic Acids Res. 1987 Jan 26;15(2):857 - PubMed
  13. Virology. 1988 Feb;162(2):483-6 - PubMed
  14. Mutat Res. 1988 May;199(1):159-65 - PubMed
  15. Science. 1988 Jul 15;241(4863):317-22 - PubMed
  16. Hum Genet. 1988 Jul;79(3):242-4 - PubMed
  17. Blood. 1989 Feb;73(2):391-6 - PubMed
  18. J Virol. 1989 Sep;63(9):3822-8 - PubMed
  19. Science. 1989 Nov 3;246(4930):629-34 - PubMed
  20. Proc Natl Acad Sci U S A. 1990 Mar;87(6):2211-5 - PubMed
  21. J Exp Med. 1990 Jul 1;172(1):355-8 - PubMed
  22. J Exp Med. 1990 Aug 1;172(2):509-2 - PubMed
  23. Curr Top Microbiol Immunol. 1992;158:97-129 - PubMed
  24. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7257-61 - PubMed
  25. Science. 1992 Nov 27;258(5087):1485-8 - PubMed
  26. Blood. 1992 Dec 15;80(12):3000-8 - PubMed
  27. Curr Opin Genet Dev. 1993 Feb;3(1):74-80 - PubMed
  28. Nat Genet. 1992 Jun;1(3):196-8 - PubMed
  29. Hum Mol Genet. 1993 Feb;2(2):123-6 - PubMed
  30. Br J Haematol. 1993 Apr;83(4):554-9 - PubMed
  31. Exp Hematol. 1993 Jul;21(7):928-33 - PubMed
  32. Nat Genet. 1993 Jun;4(2):202-5 - PubMed
  33. Hum Mol Genet. 1993 Jun;2(6):655-62 - PubMed
  34. Hum Mol Genet. 1993 Jun;2(6):797-9 - PubMed
  35. Cancer Genet Cytogenet. 1993 Aug;69(1):13-6 - PubMed
  36. Blood. 1993 Sep 15;82(6):1900-6 - PubMed
  37. Exp Hematol. 1993 Oct;21(11):1419-26 - PubMed
  38. Proc Soc Exp Biol Med. 1993 Dec;204(3):289-300 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources